Intravitreal Faricimab Injection and Macular Hole Development Risk

Rare Eye Condition Resolved After Surgery Following Faricimab Treatment

A recent medical case highlights a rare complication arising from the treatment of polypoidal choroidal vasculopathy (PCV). A male patient undergoing intravitreal faricimab therapy developed a full-thickness macular hole (FTMH) as a consequence.

Understanding the Case

PCV is an eye condition affecting the choroid, the layer of blood vessels beneath the retina. It can lead to vision loss if left untreated. Intravitreal faricimab is a medication injected directly into the eye to manage the condition.

The Unexpected Complication

In this particular instance, the patient’s treatment with faricimab unexpectedly led to the formation of an FTMH. An FTMH is a defect in the macula, the central part of the retina responsible for sharp, detailed vision.

Successful Surgical Intervention

Fortunately, the FTMH was successfully addressed through vitreoretinal surgery. This specialized surgical procedure is designed to repair retinal defects and restore vision.

Vitreoretinal Surgery Explained

• Vitreoretinal surgery involves accessing the back of the eye to repair retinal detachments, macular holes, and other conditions.
• The procedure often includes removing the vitreous gel, the clear gel that fills the eye.
• The surgeon then manipulates the retina to close the macular hole.

Final Overview

This case underscores the importance of careful monitoring and awareness of potential, albeit rare, complications associated with medical treatments. While intravitreal faricimab remains a valuable tool in managing PCV, this instance highlights the need for vigilance and prompt intervention when unexpected issues arise. The successful resolution through vitreoretinal surgery demonstrates the advancements in treating complex eye conditions.